Avoiding Headaches When Working with Multiple CDMOs and Sites Along The Drug Development Journey

The promise of an “under one roof” drug development model is appealing: lower costs, faster timelines, and fewer handoffs. But for complex therapeutics, a single-provider approach can introduce its own constraints. When sponsors are willing to orchestrate multiple partners—or multiple sites within one network—they can unlock meaningful scientific, cost, speed, and phase-specific advantages. In this session, Curia President of R&D James Grabowski draws on more than 20 years in the CDMO industry to share practical lessons, decision frameworks, and best practices for successfully managing multi-site operations and getting advanced therapies to patients faster.